$0.20 EPS Expected for AngioDynamics, Inc. (ANGO)

March 14, 2018 - By Ellis Scott

 $0.20 EPS Expected for AngioDynamics, Inc. (ANGO)
Investors sentiment decreased to 1.17 in 2017 Q3. Its down 1.32, from 2.49 in 2017Q2. It worsened, as 13 investors sold AngioDynamics, Inc. shares while 52 reduced holdings. 24 funds opened positions while 52 raised stakes. 33.36 million shares or 0.00% more from 33.36 million shares in 2017Q2 were reported.
Bessemer holds 63,200 shares or 0% of its portfolio. Pub Employees Retirement Association Of Colorado has 16,356 shares for 0% of their portfolio. Barclays Public Ltd Com holds 0% or 5,000 shares in its portfolio. Lapides Asset Limited Liability Company has 473,300 shares. Swiss Bancshares reported 61,000 shares. Parametric Portfolio Ltd Liability holds 0% or 80,752 shares. Gotham Asset Management Ltd Limited Liability Company holds 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO) or 49,193 shares. Nordea Mngmt Ab accumulated 126,040 shares. State Board Of Administration Of Florida Retirement Sys has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Renaissance Tech Lc invested 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO). Northern has invested 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO). 19,193 were accumulated by Neuberger Berman Gru Limited Liability Corporation. Ameriprise Fincl owns 639,011 shares. 28,715 are owned by Manufacturers Life Insurance Co The. Great Lakes Advsr Ltd Liability reported 281,364 shares stake.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.20 EPS on March, 29 before the open.They anticipate $0.01 EPS change or 5.26 % from last quarter’s $0.19 EPS. ANGO’s profit would be $7.35M giving it 21.24 P/E if the $0.20 EPS is correct. After having $0.16 EPS previously, AngioDynamics, Inc.’s analysts see 25.00 % EPS growth. The stock decreased 1.22% or $0.21 during the last trading session, reaching $16.99. About 164,660 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since March 15, 2017 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 8 analysts covering AngioDynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. AngioDynamics had 20 analyst reports since July 24, 2015 according to SRatingsIntel. As per Wednesday, May 31, the company rating was maintained by Canaccord Genuity. The rating was downgraded by Raymond James to “Mkt Perform” on Tuesday, November 10. On Wednesday, September 23 the stock rating was initiated by Sidoti with “Neutral”. Canaccord Genuity downgraded AngioDynamics, Inc. (NASDAQ:ANGO) on Tuesday, April 5 to “Hold” rating. The rating was upgraded by Zacks to “Sell” on Monday, August 31. The firm has “Hold” rating given on Monday, July 10 by Canaccord Genuity. Canaccord Genuity maintained the shares of ANGO in report on Friday, January 8 with “Buy” rating. The firm has “Hold” rating given on Thursday, January 4 by Canaccord Genuity. Barclays Capital initiated it with “Equal Weight” rating and $17 target in Wednesday, February 8 report. The firm earned “Hold” rating on Sunday, October 8 by Canaccord Genuity.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $624.30 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It currently has negative earnings. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

More notable recent AngioDynamics, Inc. (NASDAQ:ANGO) news were published by: Businesswire.com which released: “AngioDynamics to Report Fiscal 2018 Second Quarter Financial Results on …” on December 11, 2017, also Globenewswire.com with their article: “AngioDynamics to Present at the 2017 Morgan Stanley Global Healthcare Conference” published on August 29, 2017, Seekingalpha.com published: “AngioDynamics’ (ANGO) CEO Jim Clemmer on Q2 2018 Results – Earnings Call …” on January 04, 2018. More interesting news about AngioDynamics, Inc. (NASDAQ:ANGO) were released by: Finance.Yahoo.com and their article: “AngioDynamics (ANGO) Banks on Buyouts, Debt Level High” published on January 24, 2018 as well as Businesswire.com‘s news article titled: “AngioDynamics to Report Fiscal 2018 Third Quarter Financial Results on March …” with publication date: February 27, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.